License Agreements |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| License Agreements [Abstract] | |
| LICENSE AGREEMENTS | NOTE 3 — LICENSE AGREEMENTS
The Company’s rights to develop and commercialize APITOX in its licensed territories are derived from license and supply arrangements with Apimeds, Inc. (Korea), a related party. No new license agreements were entered into, and no material amendments were made to the Company’s existing license agreements, during the three and six months ended June 30, 2026. No milestone payments became due and no royalty obligations were incurred during the three and six months ended June 30, 2026 or 2025. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 for a description of the material terms of the Company’s license agreements. |